Article information
Full text is only aviable in PDF
References
[1.]
M.C. Ghany, D.R. Nelson, D.B. Strader, et al.
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
Hepatology, 54 (2011), pp. 1433-1444
[2.]
B.R. Bacon, S.C. Gordon, E. Lawitz, for HCV RESPOND-2 Investigators, et al.
Boceprevir for previously treated chronic HCV genotype 1 infection.
N Engl J Med, 364 (2011), pp. 1207-1217
[3.]
I.M. Jacobson, J.G. McHutchison, G. Dusheiko, for ADVANCE Study Team, et al.
Telaprevir for previously untreated chronic hepatitis C virus infection.
N Engl J Med, 364 (2011), pp. 2405-2416
[4.]
F. Poordad, J. McCone Jr., B.R. Bacon, for SPRINT-2 Investigators, et al.
Boceprevir for untreated chronic HCV genotype 1 infection.
N Engl J Med, 364 (2011), pp. 1195-1206
[5.]
K.E. Sherman, S.L. Flamm, N.H. Afdhal, et al.
Response-guided telaprevir combination treatment for hepatitis C virus infection.
N Engl J Med, 365 (2011), pp. 1014-1024
[6.]
S. Zeuzem, P. Andreone, S. Pol, for REALIZE Study Team, et al.
Telaprevir for retreatment of HCV infection.
N Engl J Med, 364 (2011), pp. 2417-2428
[7.]
K.-C. Cheng, S. Gupta, H. Wang, et al.
Current drug discovery strategies for treatment of hepatitis C virus infection.
J Pharm Pharmacol, 63 (2011), pp. 883-892
[8.]
D.N. Fusco, R.T. Chung.
New protease inhibitors for HCV – Help is on the way.
J. Hepatology, 54 (2011), pp. 1087-1089
[9.]
A.P. Desai, N. Reau.
Naives, nonresponders, relapsers: who is there left to treat?.
Clin Liver Dis, 15 (2011), pp. 483-495
[10.]
Boceprevir drug label – FDA.
[11.]
Telaprevir drug label – FDA.
[12.]
No authors listed. Telaprevir PK fact sheet 2011. University of Liverpool (Available at: www.hep-druginteractions.org).
[13.]
No authors listed. The Medical Letter 2011;53(1369):57–59.
[14.]
V. Garg, R. van Heeswijk, J.E. Lee, et al.
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
Hepatology, 54 (2011), pp. 20-27
[15.]
No authors listed. Boceprevir PK fact sheet 2011. University of Liverpool (Available at: www.hep-druginteractions.org).
[16.]
P. Cacoub, M. Bourlière, J. Lübbe, et al.
Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals.
J Hepatol, (2011),
[17.]
H. Mountataudié, T. Passeron, N. Cardot-Leccia, et al.
Drug rash with eosinophilia and systemic symptoms due telaprevir.
Dermatology, 221 (2010), pp. 303-305
[18.]
Hézode C. National French Liver Meeting, 2011 (oral presentation).
Copyright © 2011. Elsevier Editora Ltda.. All rights reserved
